ACR-246 demonstrates best-in-class 5T4-targeting ADC properties in preclinical solid tumor models

June 5, 2024

Hangzhou Adcoris BioPharma Co. Ltd. is developing ACR-246, a novel 5T4-targeted antibody-drug-conjugate (ADC), for the treatment of solid tumors.

BioWorld Science Conferences American Society of Clinical Oncology Cancer Antibody-drug conjugate Immuno-oncology

Today's news in brief

BioWorld

BioWorld briefs for May 2, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for May 2, 2025.

CMS vows to put more emphasis on MA plans’ prior authorization

BioWorld MedTech

Physicians aren’t the only ones who see prior authorization (PA) practices as a significant problem, but John Brooks, deputy administrator at CMS, told a med tech...

Filling the NIH funding gap to protect biopharma research

BioWorld

The Trump administration’s broad slash to university research budgets raises pertinent questions over impacts to the biopharma ecosystem, specifically how a...

US flag, stock market chart, White House

100 days of uncertainty

BioWorld

The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...